eli lilly retatrutide clinical trials stock jumps on Phase 3 weight loss results Retatrutide Shows 28% Weight Loss

President Trumps much-anticipated deal with GLP-1 manufacturers Eli Lilly and Novo Nordisk makes modest steps to expand patient access to the class of GLP-1 medications for the many millions of Americans who struggle with obesity

Therefore, the US Food and Drug Administration (FDA) prohibits these therapies for patients with an individual or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN2)

It has a relatively simple chemical structure and exists as a free small molecule in aqueous solution

ACA/individual-market plans are included in the 1/1/2025 exclusion

doi: 10.1210/en.2006-0153 164 BucinskaiteVTolessaTPedersenJRydqvistBZerihunLHolstJJet al